Braving The PPAR Storm, Zydus Cadila Says Its Potential Blockbuster Is Approved In India
This article was originally published in PharmAsia News
Executive Summary
Zydus Cadila scores a regulatory approval in India for Lipaglyn, a PPAR alpha/gamma dual agonist, but in a class known for cardiovascular risks the product will likely be under close scrutiny.